Psychiatry

In a study comparing readmission rates for patients with schizophrenia or schizoaffective disorder on oral or long-acting injections, investigators found after 30 days the readmission rate was 8.3% among patients who received pills and 1.9% among patients who received injections.

After undergoing cognitive behavioral therapy, unmedicated pediatric patients with anxiety disorder experienced changes in activation in the fronto-parietal network regions including left and right supplementary motor area, middle frontal gyrus, and superior parietal lobule.

A new survey study of high schoolers found alcohol, cannabis, and nicotine were linked to significant, moderate dose-dependent associations with worse symptoms of depression, anxiety, ADHD, general mental health, as well as suicidal thoughts.

A new study found behavioral activation therapy is just as effective as antidepressants for treating depressive symptoms in patients with heart failure, with both treatments having a 50% reduction at months 3, 6, and 12.

Addressing isolation and loneliness indexes resulted in a decreased risk of all-cause mortality among individuals with obesity in the UK Biobank.

In August 2023, 34.5% of mental health visits took place via video, and 10% of primary and subspecialty occurred via telemedicine (including video and/or telephone).

Respondents in trigger states had significantly greater increased anxiety and depression symptoms following the Dobbs abortion decision on June 24, 2022 than respondents in non-trigger states.

A new study found individuals aged 18 – 55 with treatment-resistant schizophrenia had significantly greater adverse events than individuals aged ≥ 55 years.

A new study found individuals with OCD had an 82% increased risk of all-cause mortality as well as an increased risk of mortality due to natural causes and unnatural causes.

In an interview, Jacob Ballon, MD, MPH, discusses the significance of his team’s study which found olanzapine and samidorphan was well-tolerable for up to 4 years of treatment for schizophrenia and bipolar disorder treatment.

The first Lungcast of 2024 touches on one of the most pressing issues in medicine: burnout, with an organizational expert.

For every increment increase in a participant’s usual score for depressive symptoms, investigators of a new study found weight increased a month later by 45g, only for participants with overweight and obesity.

A new study found, after bariatric surgery, participants had a 9.5% reduction in anxiety and a 22.3% reduction in depression.

A new study does not support the home-use tDCS since the findings show the home-use tDCS combined with either a digital psychological intervention or digital placebo was not superior to the sham.

In an interview, Hassan Dashti, PhD, RD, discusses the main takeaway of a study on anorexia nervosa being associated with the morning chronotype.

A study demonstrated olanzapine and samidorphan’s (LYBALVI) safety, tolerability, and durability during a 4-yeat treatment period.

A new study found individuals with anorexia nervosa were associated with having a morning chronotype and vice versa.

Mindfulness-Oriented Recovery Enhancement plus methadone treatment is a promising treatment option for patients with opioid use disorder, having been significantly associated with less return to drug use and methadone treatment dropout, a new study found.

Young adults aged 18 – 19 are the age range who discontinues ADHD medication the most, according to a new study.

A nationwide Taiwan-based study found benzodiazepine use during pregnancy was linked to roughly a 70% increased risk of miscarriage.

After participants with autism wore biosensors tracking physiological signals, a logistic regression predicted aggressive behaviors 3 minutes before it happened.

In a new study, children had 8 - 40% higher odds of a psychiatric condition if their parents scored 1 SD above the mean on the general psychopathology. This demonstrates how parents with psychiatric disorders have a higher likelihood of passing it down to their children.

Miller discusses the EMERGENT-2 trial and the benefits of xanomeline-trospium for treating adults with schizophrenia, for which the treatment is currently awaiting FDA decision.

Jennifer Mitchell, PhD, discusses MAPS Public Benefit Corporations’ recent New Drug Application submission for MDMA-Assisted Therapy for PTSD and what the treatment’s potential approval could mean for people with PTSD.